Cipla's Robust Financial Leap: A 30% Profit Surge in Q4 FY25
Cipla reported a 30% increase in net profit, reaching Rs 1,222 crore in Q4 FY25, fueled by higher sales in India, the US, and Africa. Total revenue rose to Rs 6,730 crore. For the full year, net profit grew 28% to Rs 5,272 crore, with a significant rise in domestic and African markets.
- Country:
- India
Cipla, a leading pharmaceutical company, announced a substantial 30% increase in its consolidated net profit for the fourth quarter of the fiscal year 2025. The profit reached Rs 1,222 crore, driven by significant sales growth in India, North America, and Africa.
The Mumbai-based firm's revenue from operations increased to Rs 6,730 crore from Rs 6,163 crore in the corresponding period of the previous year. The domestic market revenue alone saw an 8% rise to Rs 2,622 crore.
Cipla's focus is on expanding its key markets and investing in its future pipeline, according to MD and Global CEO Umang Vohra. The company also announced a total dividend of Rs 16 per share as it marks its 90th anniversary.
(With inputs from agencies.)
Advertisement
ALSO READ
Birla Corporation Shows Impressive Financial Growth and Strategic Expansion Plans
Introducing the BSE Dividend Leaders 50 Index: A New Benchmark for Consistent Dividends
IEPFA and SEBI Launch “Niveshak Shivir” to Simplify Reclaiming of Unclaimed Dividends and Shares
Aditya Birla Capital's Strong Financial Growth Sparks Positive Momentum
KRN Heat Exchanger Reports Stellar FY25 Financial Growth and Expansion Plans
Google News